Ticker brief
GSK GSK PLC-SPON ADR
Consumer, Non-cyclical · Pharmaceuticals
last close
$50.75
1 day
-0.9%
14 days
+9.1%
mkt cap
$107.5B
signals 14d
13
authors 14d
9
crowd 14d
-0.4σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 28% mid · 55 pctile own 1y | IV/HV 1.11× |
| Skew — 25Δ RR 30d | -0.075 7 pctile own 1y | puts bid vs calls (downside bid) |
| Net dealer OI (NDOI) | +0.05 thin | 5-session Δ +0.01 (as of 2026-07-16) |
| OI alarm | quiet | last alarm 2026-04-29 (z=6.8) |
Sentiment — last 14 days
daily mean sentiment, 2026-10-06 → 2026-10-16 · now +0.00 (−1 bearish … +1 bullish)
Who spoke9
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @BiopharmIQ | B | · | 3 | +0.00 |
| @fwpharma | B | -1.91 | 2 | +0.15 |
| @Tickeron | C | +1.53 | 2 | +0.15 |
| @CHItrader | B | -0.22 | 1 | +0.55 |
| @MMMTwealth | A | -0.39 | 1 | +0.10 |
| @AlertsAndNews | C | -3.92 | 1 | -0.15 |
| @proactive_x | C | -1.13 | 1 | -0.10 |
| @harry03994688 | A | -0.16 | 1 | +0.05 |
| @OracleNYSE | C | +0.83 | 1 | +0.00 |
Recent signals13of 13 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @BiopharmIQ | +0.00 | The tweet lists upcoming October FDA decision dates for three companies. | +2.5% | tweet ↗ |
| 2026-10-16 | @OracleNYSE | +0.00 | Tags GSK but reports Novartis terminating a Fabhalta trial, making the affected ticker ambiguous. | +2.5% | tweet ↗ |
| 2026-10-14 | @fwpharma | -0.20 | GSK plans to cut more than 1,200 Belgian jobs in a cost-saving drive. | +6.0% | tweet ↗ |
| 2026-10-13 | @harry03994688 | +0.05 | Reports named ALK7 programs and clinical-development timelines | +9.7% | tweet ↗ |
| 2026-10-13 | @proactive_x | -0.10 | RBC expects an in-line quarter, with HIV strength offsetting vaccine headwinds. | +9.7% | tweet ↗ |
| 2026-10-12 | @BiopharmIQ | +0.00 | Lists explicit October FDA decision dates for three drug candidates. | +8.2% | tweet ↗ |
| 2026-10-12 | @Tickeron | +0.20 | Contrasts GSK's pipeline acceleration and cost savings with Novartis's scale, growth and patent risks. | +8.2% | tweet ↗ |
| 2026-10-12 | @Tickeron | +0.10 | Contrasts GSK's value and income with Lilly's stronger momentum, growth and Buy consensus. | +8.2% | tweet ↗ |
| 2026-10-07 | @AlertsAndNews | -0.15 | A broad federal vaccine-injury research and reporting initiative is being launched. | +7.9% | tweet ↗ |
| 2026-10-07 | @MMMTwealth | +0.10 | Calls CBRS good value below $180 and argues CS-4 speed creates premium AI-inference demand. | +7.9% | tweet ↗ |
| 2026-10-06 | @fwpharma | +0.50 | GSK's Cabenuva records a positive outcome in unsuppressed HIV. | +8.9% | tweet ↗ |
| 2026-10-06 | @BiopharmIQ | +0.00 | Provides explicit October PDUFA dates for five drug candidates across four issuers. | +8.9% | tweet ↗ |
| 2026-10-06 | @CHItrader | +0.55 | Cabenuva met its primary endpoint and showed lower viral rebound than daily oral therapy. | +8.9% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.